Fact based stock research
Dr. Lal PathLabs (BSE:539524)

INE600L01024

Dr. Lal PathLabs stock research in summary

lalpathlabs.com


Dr. Lal PathLabs shares are more expensive than other comparable stocks. They show above average growth and are safely financed, but are poor value. We recommend evaluating whether the future of the company Dr. Lal PathLabs is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.


Latest Obermatt Ranks


Country India
Industry Health Care Services
Index
Size class Small

October 7, 2021. Stock data may be delayed. Login to get the most recent research.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Dr. Lal PathLabs from October 7, 2021.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.